Z-VAD(OMe)-FMK

187389-52-2

C22H30FN3O7

DMSO : 100 mg/mL (213.91 mM; Need ultrasonic)

Apoptosis

Z-VAD(OMe)-FMK is a cell-permeable and irreversible pan-caspase inhibitor. IC50 & Target: pan-caspase^[1] In Vitro: Z-VAD(OMe)-FMK is a broad-spectrum caspase inhibitor, has been shown to inhibit the intracellular activation of caspase-like proteases. The injection of Z-VAD(OMe)-FMK suppresses the caspase-3 activity in lung tissues, and significantly decreases the number of terminal dUTP nick-end labeling-positive cells^[1]. Z-VAD(OMe)-FMK is administered intraperitoneally at 1 hour before and 6 hours after SAH. Expression of caspase-3 and positive TUNEL is examined as markers for apoptosis. Z-VAD(OMe)-FMK suppresses TUNEL and caspase-3 staining in endothelial cells, decreases caspase-3 activation, reduces BBB permeability, relieves vasospasm, abolishes brain edema, and improves neurological outcome^[2]. Z-VAD(OMe)-FMK is a cell-permeable caspase inhibitor, efficiently blocks cell death induced by SMN deficiency^[3]. In Vivo: The survival rate of mice is prolonged significantly by the injection of Z-VAD(OMe)-FMK. All mice succumbed to LPS within 30 hours. By contrast, the mice treated with Z-VAD(OMe)-FMK survive significantly longer and 27% of the mice survived more than 7 days^[1].